This forgotten pandemic stock hasn't said its last word.

BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares. ・The update followed the ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update ...

Investing.com -- Moderna (NASDAQ:MRNA) stock rose 10% on Thursday, extending its winning streak to a fourth consecutive session and reaching its highest intraday level since November 2024.

Moderna Inc. (MRNA) stock reached a significant milestone, hitting a 52-week high of $45.44. This achievement marks a notable point in the company’s performance over the past year. According to ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a Buy.